Butyrate, produced by beneficial bacteria such as Faecalibacterium prausnitzii and Roseburia spp., has been shown to inhibit NF-κB activation, a major driver of intestinal inflammation in IBD [34]. Here, NFKB1 is linked to inflammatory bowel disease.